Dianthus Therapeutics, Inc. /DE/ (DNTH) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$73.55

From 52W high−35.72%

Volume972522.00

Market cap$4.17B

P/E (TTM)—

P/S (TTM)2189.8x

Div yield—

Key dataOct 19, 2026

Open

$73.55

From 52W high

−35.72%

Volume

972522.00

Market cap

$4.17B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−111.2x

P/E (TTM)

—

RSI (14)

25.1

MomentumView details →

1D Return

+3.40%

YTD Return

+82.61%

SummaryUpdated Jun 1, 2026

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is a clinical-stage biotechnology company founded in 2015 and headquartered in New York, New York. The company went public in June 2018 and focuses on developing novel monoclonal antibody treatments for patients suffering from severe autoimmune and inflammatory diseases. Dianthus is currently advancing its lead drug candidate, DNTH103, through Phase 1 clinical trials for multiple neurological conditions including generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

Ask drillr about Dianthus Therapeutics, Inc. /DE/ →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−111.2x

EV/Sales

1724.7x

P/S (TTM)

2189.8x

P/B (TTM)

3.6x

ProfitabilityView details →

Gross Margin

96.01%

Net Margin

−1570.85%

EBITDA Margin

−1550.95%

ROE (TTM)

−2.55%

ROA (TTM)

−2.47%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−60.77%

EPS YoY

+96.00%

FCF YoY

−55.15%

Revenue CAGR 3Y

−31.80%

EPS CAGR 3Y

−64.71%

EBITDA YoY

+75.90%

MomentumView details →

1D Return

+3.40%

YTD Return

+82.61%

1Y Return

+109.04%

RSI (14)

25.1

vs 50D SMA

−23.71%

vs 200D SMA

−9.58%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

26.10x

Quick Ratio

26.10x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.90

EPS Surprise

−6.35%

Beats (12Q)

4/12

Next Q EPS Est

−$1.07

Avg Surprise (4Q)

−8.49%

Rev Surprise

156.07%

Financials snapshotView financials →

Revenue (TTM)

1.90M

Net Income (TTM)

−29.91M

Op. CF (TTM)

−155.38M

Next earningsNov 5, 2026 →

Latest newsMore news →

Dianthus Therapeutics is advancing DNTH312, a first-in-class bifunctional fusion protein, aiming to be Phase 1 ready by year-end 2027.76d ago

Dianthus Therapeutics is advancing DNTH212 for Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis, with Phase 1 healthy volunteer data anticipated by year-end 2026.76d ago

Similar companies

Edgewise Therapeutics, Inc.EWTX Jacobio Pharmaceuticals Group Co., Ltd.01167.HK Ocumension Therapeutics01477.HK 华恒生物688639.SH Arcutis Biotherapeutics, Inc.ARQT Tango Therapeutics, Inc.TNGX Find similar companies →

Latest newsMore news →

Dianthus Therapeutics is advancing DNTH312, a first-in-class bifunctional fusion protein, aiming to be Phase 1 ready by year-end 2027.76d ago Dianthus Therapeutics is advancing DNTH212 for Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis, with Phase 1 healthy volunteer data anticipated by year-end 2026.76d ago